HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Combination treatment with temozolomide and thalidomide inhibits tumor growth and angiogenesis in an orthotopic glioma model.

Abstract
The chemotherapeutic agent temozolomide (TMZ) and the anti-angiogenic agent thalidomide (THD) have both demonstrated anti-tumor activity in patients with recurrent malignant glioma. Combination treatment with TMZ and THD in patients with glioblastoma multiforme (GBM) appears to be more effective than treatment with either drug alone. To investigate the mechanism of this anti-tumor effect, we examined the combined effects of TMZ and THD in a rat glioma xenograft model. We found that combination treatment markedly inhibited the growth of tumors that were orthotopically implanted into rat brains. Using proliferating cell nuclear antigen (PCNA) staining, we observed a significant decrease in cell proliferation in these tumors. CD31 staining of the microvasculature revealed a significant decrease in angiogenesis. We also found increased apoptosis in treated tumors by terminal deoxynucleotidyl-mediated deoxyuridine triphosphate nick-end labeling (TUNEL) assay. We further demonstrated that the expression of angiogenic factors, such as vascular endothelial cell growth factor (VEGF) and basic fibroblastic growth factor (bFGF), were inhibited by THD. THD also decreased the number of ED1-positive, activated macrophages or microglial cells, which produce pro-angiogenic molecules around the glioma. Taken together, these results suggest that combination treatment with TMZ and THD inhibits tumor growth via the induction of apoptosis and the inhibition of angiogenesis in a rat model and may be a promising therapy for malignant gliomas.
AuthorsMyung Jin Son, Jong-Soo Kim, Mi Hyun Kim, Hyun Seok Song, Ji Tae Kim, Heechul Kim, Taekyun Shin, Hyun Jung Jeon, Dong-Sup Lee, Shi-Young Park, Yung-Jin Kim, Jong-Hyun Kim, Do-Hyun Nam
JournalInternational journal of oncology (Int J Oncol) Vol. 28 Issue 1 Pg. 53-9 (Jan 2006) ISSN: 1019-6439 [Print] Greece
PMID16327979 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Angiogenesis Inhibitors
  • Antineoplastic Agents, Alkylating
  • Thalidomide
  • Dacarbazine
  • Temozolomide
Topics
  • Angiogenesis Inhibitors (pharmacology)
  • Animals
  • Antineoplastic Agents, Alkylating (pharmacology)
  • Apoptosis (drug effects)
  • Brain Neoplasms (drug therapy)
  • Cell Proliferation
  • Dacarbazine (analogs & derivatives, pharmacology)
  • Gene Expression Profiling
  • Glioma (drug therapy)
  • Humans
  • In Situ Nick-End Labeling
  • Neovascularization, Pathologic
  • Rats
  • Rats, Sprague-Dawley
  • Temozolomide
  • Thalidomide (pharmacology)
  • Transplantation, Heterologous

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: